If the hybrid and “diverse” small molecule, RRx-001 (nibrozetone) could spit in a vial and ship it off to 23andMe, a DNA mapping service that extracts genealogical data from saliva, the breakdown would read as follows:
50% Western United States where it was conceived—in Utah and California at the aerospace contractor, ATK, and at RadioRx (now EpicentRx), respectively.
30% Western Europe where it is manufactured deep underground because of the explosivity risk.
5% East Asia where it is in an ongoing Phase 3 clinical trial REPLATINUM for the treatment of small cell lung cancer (SCLC).
5% throughout the whole United States where it will start a Phase 2b clinical trial for the mitigation/prevention of severe oral mucositis in head and neck cancer.
2.5% Australia where the small molecule is under intensive investigation as an anti-neurodegenerative agent.
2.5% England where it will start a clinical trial for the treatment of endometriosis.